Tech.AD USA มอบรางวัลอันดับหนึ่งในประเภทเซ็นเซอร์และการรับรู้ให้แก่ LeddarTech สำหรับซอฟต์แวร์ LeddarVision ADAS และการขับขี่แบบอัตโนมัติ

ควิเบกซิตี้, Nov. 30, 2022 (GLOBE NEWSWIRE) — LeddarTech®ผู้นำระดับโลกด้านการจัดหาเทคโนโลยีซอฟต์แวร์ ADAS และการขับขี่แบบอัตโนมัติที่ยืดหยุ่น แข็งแกร่ง และแม่นยำที่สุด มีความยินดีที่จะประกาศว่า LeddarVision™ ซึ่งเป็นโซลูชันการฟิวชันเซ็นเซอร์ระดับต่ำและการรับรู้ได้รับรางวัล Sensor Perception ซึ่งเป็นรางวัลที่เป็นที่ต้องการอย่างมากจาก Tech.AD USA เมื่อวันที่ 14 พฤศจิกายน 2022 ที่เมืองดีทรอยต์ สำหรับอีเวนต์นี้ แพลตฟอร์มแลกเปลี่ยนความรู้ชั้นนำในอเมริกาเหนือได้รวบรวมผู้มีส่วนได้ส่วนเสียหลักที่มีบทบาทอย่างแข็งขันในอุตสาหกรรมยานยนต์อัตโนมัติมาร่วมงาน ในบรรดาการสมัครทั้งหมดที่มีการเสนอเข้ามานั้น โครงการที่ดีที่สุดจำนวนเก้าโครงการได้รับการเสนอชื่อโดยคณะกรรมการผู้เชี่ยวชาญระดับนานาชาติ ซึ่งเป็นการนำเสนอชื่อสำหรับรอบสุดท้ายซึ่งครอบคลุมประเภทต่าง ๆ สามประเภทที่แตกต่างกัน

โดยจะมีการจัดแสดง LeddarCar™ ซึ่งจะเป็นยานพาหนะสาธิตการใช้งานจริงบนท้องถนนของ LeddarTech ที่ติดตั้งซอฟต์แวร์ LeddarVision ภายในงาน LeddarVision เป็นโซลูชันเกรดยานยนต์ที่ปรับใช้ให้ทำงานร่วมกับเซนเซอร์ได้เป็นอย่างดีซึ่งมีประสิทธิภาพสูง ซึ่งมอบแบบจำลองสิ่งแวดล้อม 3 มิติที่มีความแม่นยำสูง จึงช่วยให้สามารถทำงานอัตโนมัติในระดับ 2-5 ได้ ในระหว่างอีเวนต์นี้ ผู้เชี่ยวชาญทางเทคนิคของ LeddarTech ได้แสดงให้เห็นว่าเทคโนโลยีฟิวชันระดับต่ำช่วยลดความซับซ้อนของชุดเซ็นเซอร์และลดการพึ่งพาฮาร์ดแวร์ เพื่อให้ลูกค้ามีความยืดหยุ่นในการปรับขนาดและส่งมอบประสิทธิภาพ ADAS และการขับขี่แบบอัตโนมัติที่ดียิ่งขึ้นได้อย่างไร

“ผู้ชนะได้สร้างมาตรฐานใหม่ให้กับนวัตกรรมและเทคโนโลยีที่สร้างสรรค์ในอุตสาหกรรมการขับขี่อัตโนมัติ” Davina Thalmann โปรดิวเซอร์ของ Tech.AD USA 2022 กล่าว “รางวัลนี้เป็นข้อพิสูจน์ถึงทักษะ ความเฉลียวฉลาด และวิสัยทัศน์ของผู้สร้าง ความสามารถที่จะนำเสนออนาคตแบบเรียลไทม์ได้นั้นถือว่าเป็นข้อได้เปรียบอย่างแท้จริง” เธอกล่าวเสริม

“รางวัลนี้ช่วยเพิ่มการยอมรับในระดับนานาชาติอันน่าทึ่งที่ LeddarTech ได้รับสำหรับโซลูชันซอฟต์แวร์ฟิวชันเซ็นเซอร์และการรับรู้ของเรา” คุณ Charles Boulanger ซีอีโอของ LeddarTech กล่าว “ในปีนี้ เทคโนโลยี LeddarVision ของเรายังได้รับการยอมรับจาก Volkswagen Group Innovation Tel Aviv 2022 Konnect และ CARIAD Startup Challenge รวมถึง Shenzhen Automotive Electronics Industry Association อีกด้วย” คุณ Boulanger กล่าวต่อ “อีกทั้งผมยังภูมิใจกับรางวัลองค์กรที่ทางเราเป็นเกียรติได้รับ โดยเราได้รับการยกย่องให้เป็นหนึ่งใน “บริษัทที่เติบโตเร็วที่สุดแห่งปี 2022″ โดยคณะกรรมการ CEO Views และได้รับการเสนอชื่อให้เป็น “หนึ่งในบริษัทที่มีการเติบโตสูงสุดของแคนาดา” โดย Report on Business ของ Globe and Mail รางวัลต่าง ๆ นั้นถือเป็นการให้การยอมรับต่อทีมงานของเราทั่วโลก ซึ่งมุ่งมั่นพัฒนาโซลูชันที่ช่วยเพิ่มความปลอดภัยและสนับสนุนลูกค้าของเราด้วยความซื่อตรงและใจอันรักยิ่ง” เขากล่าวสรุป

เกี่ยวกับ LeddarTech

LeddarTech เป็นบริษัทซอฟต์แวร์ระดับโลกที่ก่อตั้งขึ้นในปี 2007 โดยได้พัฒนาและจัดหาโซลูชันการรับรู้ที่ครอบคลุมซึ่งช่วยเปิดใช้งานการปรับใช้ ADAS และแอปพลิเคชันการขับขี่อัตโนมัติ เทคโนโลยีซอฟต์แวร์เกรดยานยนต์ของ LeddarTech ใช้อัลกอริทึมการมองเห็นของคอมพิวเตอร์และ AI เพื่อสร้างแบบจำลองสภาพแวดล้อม 3 มิติที่มีความแม่นยำสูง ซึ่งจะช่วยให้ตัดสินใจได้ดีขึ้น อีกทั้งยังช่วยให้การนำทางปลอดภัยยิ่งขึ้นอีกด้วย เทคโนโลยีประสิทธิภาพสูง ปรับขนาดได้ และคุ้มค่านี้ใช้ประโยชน์จาก OEM และซัพพลายเออร์ระดับ 1-2 เพื่อการใช้งานโซลูชันยานยนต์และรถออฟโรดได้อย่างมีประสิทธิภาพ

LeddarTech เป็นผู้รับผิดชอบในการคิดค้นนวัตกรรมใหม่ ๆ ในด้านยานยนต์และการเคลื่อนที่ระยะไกลที่ทันสมัย ด้วยเทคโนโลยีทั้งที่จดสิทธิบัตรแล้วหรือที่รอการอนุมัติมากกว่า 140 รายการที่ช่วยเสริมขีดความสามารถ ADAS และการขับขี่แบบอัตโนมัติ การรับรู้ที่เชื่อถือได้มีความสำคัญอย่างยิ่งในการทำให้ยานยนต์ทั่วโลกปลอดภัยขึ้น มีประสิทธิภาพมากขึ้น ยั่งยืน และราคาไม่แพง นี่จึงเป็นสิ่งที่ผลักดันให้ LeddarTech กลายเป็นโซลูชันซอฟต์แวร์ฟิวชันเซ็นเซอร์และการรับรู้ที่ได้รับการยอมรับอย่างกว้างขวางที่สุด

ดูข้อมูลเพิ่มเติมเกี่ยวกับ LeddarTech ได้ที่ www.leddartech.com และบน LinkedIn, Twitter, Facebook และ YouTube.

ติดต่อ:
Daniel Aitken รองประธานฝ่ายการตลาดระดับโลก การสื่อสาร และนักลงทุนสัมพันธ์ของ LeddarTech Inc.
โทร.: + 1-418-653-9000 ต่อ 232 daniel.aitken@leddartech.com

ติดต่อนักลงทุนสัมพันธ์และเว็บไซต์:InvestorRelations@leddartech.comhttps://investors.leddartech.com/

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator และโลโก้ที่เกี่ยวข้องเป็นเครื่องหมายการค้าหรือเครื่องหมายการค้าจดทะเบียนของ LeddarTech Inc. และบริษัทในเครือ แบรนด์ ชื่อผลิตภัณฑ์ และเครื่องหมายอื่น ๆ ทั้งหมดเป็นหรืออาจเป็นเครื่องหมายการค้าหรือเครื่องหมายการค้าจดทะเบียนที่ใช้เพื่อระบุผลิตภัณฑ์หรือบริการของเจ้าของที่เกี่ยวข้อง

สามารถดูรูปภาพประกอบประกาศนี้ได้ที่ https://www.globenewswire.com/NewsRoom/AttachmentNg/a85bc5a0-ac25-471f-9cce-43c1b03ef374

GlobeNewswire Distribution ID

Amlan International Adds Sales Manager, Distribution Partner and is Granted New Registration of Calibrin-Z in the Philippines

CHICAGO, Nov. 29, 2022 (GLOBE NEWSWIRE) — Amlan International, the animal health business of Oil-Dri® Corporation of America, is pleased to announce exciting new developments for their business in the Philippines. Jayson Fernandez joined Amlan as a sales manager for the Philippines in January 2022 and FJ Wegon Animal Health and Nutrition Inc. is now registered to distribute proven biotoxin binder Calibrin®-Z. Registration is pending of additional high-value feed additives, such as patented Varium®, designed for poultry feed efficiency.

The Philippines is the fourth-largest poultry producer in Southeast Asia, producing 1.4 million tons of broiler meat in 2020, and the third-largest swine producer in Asia, producing 1.5 million tons of pork meat. However, these production achievements have not been without challenges. The poultry industry is still recovering from COVID-19 disruptions, and swine repopulation efforts are continuing after African swine fever outbreaks.

“As producers in the Philippines continue to navigate industry challenges, Amlan is focused on providing animals with better gut protection to enhance their overall health, while also improving the bottom line,” said Dr. Wade Robey, Vice President, Agriculture & Amlan Marketing. “Jayson joining our team helps ensure long-term value and profitability for our customers in the Philippines.”

In his current role, Jayson advocates the benefits of Amlan’s mineral technology which helps to protect the intestinal linings of poultry and livestock. The core of Amlan’s products is the unique, single-sourced, calcium montmorillonite with naturally occurring opal-CT lepisheres. Vertical integration allows Oil-Dri and Amlan to control every step of the mineral production process to reliably deliver safe, high-quality, and efficacious feed additives to the global market.

Jayson has 14 years of experience in poultry breeder and broiler operations, including time as a farm operations manager in Qatar and the Kingdom of Saudi Arabia. He also served as a technical manager for a well-known global poultry pedigree breeding company. Before joining Amlan, Jayson was a private consultant for various poultry growers in the Philippines and managed sales for a local distributor of an American and European poultry equipment brand.

“As our animal health business continues to grow, so does our commitment to providing our key customers with local sales support and distributors,” said Dan Jaffee, President, and CEO of Oil-Dri and President and General Manager of Amlan. “Jayson will be available to answer any questions our customers in the Philippines have about the performance of our products and how to apply them economically and most effectively.”

Company Information

Amlan is the animal health business of Oil-Dri Corporation of America, leading global manufacturer and marketer of sorbent minerals. Oil-Dri leverages over 80 years of expertise in mineral science to selectively mine and process their unique mineral for consumer and business-to-business markets. Oil-Dri Corporation of America doing business as “Amlan International” is a publicly traded stock on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives across the world. Product availability may vary by country, associated claims do not constitute medical claims and may differ based on government requirements.

Reagan Culbertson
Media Contact
press@amlan.com

GlobeNewswire Distribution ID 8705506

Conagen develops high-purity non-GMO sulforaphane by bioconversion

Commercial production is underway for 2023.

Bedford, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) — Expanding on its portfolio of innovative nutritional products through biotechnology, Conagen, announced the development of its 99% high-purity sulforaphane. Made by a proprietary bioconversion technology, the company plans to begin the commercialization path in 2023. Conagen’s bioconversion methods enable the production of sustainable products from many naturally occurring compounds regardless of rarity or small quantities occurring in nature.

“As a supplement product, Conagen’s high-purity sulforaphane is appealing to consumers as the levels found in raw vegetables are too low to realize many of its promising health benefits,” said Casey Lippmeier, Ph.D., senior vice president of innovation. “We’re looking forward to expanding the nutritional market by commercializing sulforaphane in 2023.”

Sulforaphane has been associated with supporting health benefits against cancer, diabetes, digestion, and heart disease and promoting cognition. With biotechnology and biomanufacturing advancements, much like Conagen’s bioconversion technology, more nutritional offerings are produced at a high-quality and global scale.

Sulforaphane is found in cruciferous vegetables such as arugula, bok choy, broccoli, Brussels sprouts, cabbage, kale, radish, and more. In these vegetables, the inactive form of glucoraphanin belongs to the glucosinolate family of plant compounds. The sulfur-rich sulforaphane is activated only when vegetables are chewed or chopped to release myrosinase, a class of enzymes that play a role in the defense response of plants.

“Through Conagen’s bioconversion technology, we’re uncovering the great potential in sulforaphane as a powerful active health ingredient for consumers who are personalizing nutrition to support health functions,” said Lippmeier. “We can make safe and high-quality nutritional ingredients from natural sources and offer it at a global-scale cost-competitively so that brands may pass on the good health and savings to their consumers.”

Conagen’s sulforaphane is ideal for non-GMO supplement solutions to formulate products with a sustainable and natural consumer appeal. More research is emerging for understanding the optimistic effects on multiple health functions. As one example of many, biotechnology and biomanufacturing will continue to harness the power of biology and nature to develop and deliver solutions for better nutrition, health, and wellness. Conagen is expanding its sustainable, nutritional products portfolio to better humankind and the planet.

About Conagen
Conagen is making the impossible possible. Our scientists and engineers use modern synthetic biology tools to program micro-organisms and enzymes on a molecular level to produce high-quality, sustainable, natural products manufactured worldwide via precision fermentation and bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceuticals, and renewable materials.

Attachments

Ana Arakelian, Head of Public Relations and Communications
Conagen
+1-781-271-1588
ana.arakelian@conagen.com

GlobeNewswire Distribution ID 8705501

Azerion sets out its future strategic priorities

Amsterdam, 30 November 2022 – Today, Azerion has set out its strategic priorities in the journey to become the go-to-partner for advertisers for an easy-to-use, competitively priced and brand-safe digital environment. The Strategy Deep Dive presentation is available on www.azerion.com/investors.

Umut Akpinar, co-CEO of Azerion, comments: “I am excited to share details on our vision, mission and strategy with the market today, and all the levers we are pulling to deliver profitable organic growth. The fundamentals for the digital advertising market are strong, as audiences move more and more to digital. Our value proposition to advertisers, digital publishers, game creators and consumers makes us a truly innovative and differentiated platform and as we gain market share, we are set to continue delivering organic growth.”

Atilla Aytekin, co-CEO of Azerion, comments: “We have successfully completed 9 acquisitions so far this year, with the primary purpose of complementing our organic growth. With these acquisitions we can expand our offerings to advertisers and publishers from day 1 and, furthermore, we unlock exciting cross-selling opportunities across our platform. As our M&A pipeline becomes increasingly attractive under current macroeconomic conditions, we are assessing options to accelerate our growth.”

Strong business fundamentals
With an increasing number of internet users, research indicates that the digital advertising market is expected to deliver a CAGR of 14%, reaching a total market size of $800 billion by 2026. Despite the growth prospects, the digital advertising supply chain is still highly fragmented, with multiple layers between advertisers and digital publishers. Azerion is set to be a consolidator in this market and offer one integrated value proposition to advertisers becoming their go-to-partner for easy-to-use, competitively priced and brand-safe digital environment.

Unparalleled value proposition to advertisers
Azerion’s unique value proposition to advertisers is the integration of 5 core elements: content, audience reach, technology, creative ad formats and personal support.
With curated content that creates a brand-safe environment and reach audiences that exceed 500 million monthly active users (non-game and game audiences), integrated technology that runs 1 billion auctions every hour, creative ad formats that drive up to 20 times more user engagement and local teams that give unique support to optimise advertisers’ campaigns, Azerion strives to deliver enhanced returns on investment for advertisers.

Winning integrated platform business model
Advertisers seek audiences, while audiences seek content. Azerion’s integrated platform partners with digital publishers and game creators to bring content to consumers and work with advertisers. Azerion’s business model was developed around engaging audiences, and games were the way into audiences’ hearts. That is why Azerion is proud of its game content, which generates valuable insights into consumer behavior and unlocks a compelling extended value proposition to advertisers, who are seeking to engage with their audiences in the digital space, including in the metaverse and using digital collectibles.
Areas of growth for Azerion’s game content include the metaverse and the GameDistribution business, which partners with over a thousand game creators, in particular large studios seeking to unlock new revenue streams with free-to-play casual games.

Financial framework and performance
Azerion is reconfirming its 2022 revenue guidance of at least EUR 450 million, while also indicating that Adjusted EBITDA is expected to be above EUR 50 million.
While organic revenue growth remains a priority, improving profitability remains the main area of focus. With the listing and acquisitions, the cost base has gone up and Azerion expects to optimise costs by further integrating past acquisitions. Other levers to improve margins include growing sales volumes in direct sales to advertisers as well as publisher monetisation services, continuously developing new features that enhance user experience and increasing revenue per user in premium games.

Compelling growth prospects
As Azerion gains market share, it expects to grow organically. In addition to the organic growth opportunities, Azerion is working on an attractive pipeline of acquisitions. During the Strategy Deep dive, some examples will be shared to show how Azerion is extracting value from its acquisitions.

Join the webcast
The Strategy Deep Dive will consist of an online webcast, with a presentation from members of Azerion’s leadership team, followed by Q&A. The whole event is expected to last from 14:00 to 16:00 CET. Registrations are open via www.azerion.com/investors. The full presentation will be made available on the Azerion website shortly after the end of the Strategy Deep Dive.

Contact:
Investor Relations
ir@azerion.com

Media
press@azerion.com

DISCLAIMER
The companies in which Azerion Group N.V. directly and indirectly owns investments are separate legal entities. In this announcement “Azerion”, “Azerion Group” and “Group” are sometimes used for convenience where references are made to Azerion Group N.V. and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to Azerion Group N.V. and its subsidiaries in general or to those who work for them.

This press release is for information purposes only. The information contained in this press release does not purport to be full or complete and, in particular, is not intended to form the basis of any investment decision. No reliance may be placed by any person for any purpose on the information contained in this press release or its accuracy, fairness or completeness. Azerion will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided.

This press release may include forward-looking statements. All statements other than statements of historical facts may be forward-looking statements. Words and expressions such as believes, estimates, plans, projects, anticipates, expects, intends, may, will, should or other similar words or expressions are typically used to identify forward-looking statements. Forward-looking statements are subject to risks, uncertainties and other factors that are difficult to predict and that may cause the actual results of Azerion to differ materially from future results expressed or implied by such forward-looking statements. Any forward-looking statements reflect Azerion’s current views and assumptions based on information currently available to Azerion’s management. Forward-looking statements speak only as of the date they are made, and Azerion does not assume any obligation to update such statements, except as required by law. No assurances can be given that the forward-looking statements will be realised. No representation or warranty is made that any of these forward-looking statements will come to pass or that any estimated result will be achieved. Accordingly, no undue reliance should be placed on any forward-looking statements.

GlobeNewswire Distribution ID 1000769602

Nominations Open for the Merkin Prize in Biomedical Technology

Merkin Prize Logo

CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) — Nominations are now open for the first award of the Richard N. Merkin Prize in Biomedical Technology, which recognizes novel technologies that have improved human health.

Each year, the prize will celebrate a novel technology and recognize up to four key individuals and/or teams who contributed to the development of the technology, with a cash award of $400,000 to be shared among each year’s recipients. The winning technology must have made a demonstrable real-world impact on human health by improving the treatment, diagnosis, or prevention of disease.

The Merkin Prize is administered by the Broad Institute of MIT and Harvard, one of the world’s leading biomedical research institutes.

“The Merkin Prize will highlight the inventors of an important medical technology and will demonstrate how their work is transforming healthcare,” said Harold Varmus, chair of the selection committee. Varmus is the Lewis Thomas University Professor at Weill Cornell Medicine, a senior associate at the New York Genome Center, and a recipient of the Nobel Prize in Physiology or Medicine for his work on the origins of cancer.

“Incentivizing outstanding researchers with prizes that recognize the importance of science and technology that continue to impact human health is a goal of mine and I’m honored to acknowledge such critically important work,” said Dr. Merkin. “Additionally, I hope it will inspire younger researchers as they move forward with exciting opportunities to transform and improve our health and the quality of our lives.”

Eligibility for receipt of the Merkin Prize extends to all living investigators from anywhere in the world, from any discipline in academia, the commercial sector, or the government. Anyone may submit a nomination, but self-nominations are not permitted. Nominations must be submitted by Jan. 30, 2023.

For further information, detailed instructions, and a nomination form, please visit merkinprize.org.

About the Merkin Family Foundation

The Merkin Family Foundation was founded by visionary healthcare executive Richard Merkin, MD.

Richard Merkin, MD, is the founder and CEO of Heritage Provider Network, Inc. (HPN). HPN is the largest physician-owned managed care organization in the country dedicated to value-based healthcare delivery improvements. HPN develops and manages coordinated, patient-doctor centric, integrated healthcare systems that offer some of the strongest solutions for the future of health, care, and cost in the United States. HPN and its affiliates operate in New York, California, and Arizona, providing high-quality, cost-effective healthcare with over one million patient members. HPN is dedicated to quality, affordable healthcare, and putting patients’ wellness first.

About Broad Institute of MIT and Harvard

Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods, and data openly to the entire scientific community.

Founded by MIT, Harvard, Harvard-affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff, and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide.

Contact Information:
Karen Zusi-Tran
kzusi@broadinstitute.org

Related Images

Image 1: Merkin Prize Logo

The Richard N. Merkin Prize in Biomedical Technology is accepting nominations until Jan. 30, 2023.

This content was issued through the press release distribution service at Newswire.com.

Attachment

GlobeNewswire Distribution ID 8704630

Alchip Technologies Q3 Revenue Sets Fiscal Year ’22 Record

Operating Income and Net Income Up Year-on-Year

Taipei, Taiwan, Nov. 29, 2022 (GLOBE NEWSWIRE) — Alchip Technologies set a fiscal year 2022 record with Q3 revenue reaching $117.5 million, reflecting a year-on-year increase of 28 percent over Q3 2021 revenue of $94.1 million, and a quarter-on-quarter increase of 16.2 percent over Q2 2022 revenue of $101.1 million.

Operating income for Q3 2022 is $18.6 million, representing a 21.9 percent year-on-year increase over Q3 2021 results of $14.4 million, but a decline of 3.6 percent from Q2 2022 operating income of $19.3 million.

Net income for Q3 2022 is $14.5 million, equating to a year-over-year increase of 12.6 percent over Q3 2021 net income of $12.9 million, and a slight 0.5 percent increase over Q2 2022 net income of $14.49 million.

Advanced technology, production and designs for 7nm and smaller line-width, accounted for 69 percent of Q3 2022 revenue and 66 percent of revenue for fiscal 2022 to date.  High-performance computing applications drove 78 percent of Q3 2022 revenue and 78 percent of revenue for fiscal year to date.

For the second consecutive quarter, North America, accounted for the largest share of Q3 2022 revenue at 39 percent, followed by Asia Pacific at 38 percent.  For fiscal year 2022, North America markets contributed 36% of revenue, after accounting for only 14 percent for all of 2021.

Management reports that Q3 revenue came mildly lower than expected because production revenue still suffered from tight ABF substrate supply constraints.

“On the other hand, design demand remained robust as most of the projected milestones came in on schedule, but profit margin was down due to a higher percentage of production revenue and other one-time expenses,” explained Alchip President and CEO, Johnny Shen.

Alchip is traded on the Taiwan stock exchange.  The company is extremely well respected in North America, Japan, Israel, Taiwan, and China for its high-performance ASIC design methodology, flexible business model, best-in-class IP portfolio and advanced packaging technology expertise.

For a more information on Alchip, go to www.alchip.com

About Alchip

Alchip Technologies Ltd., founded in 2003 and headquartered in Taipei, Taiwan, is a leading global provider of silicon and design and production services for system companies developing complex and high-volume ASICs and SoCs.  The company provides faster time-to-market and cost-effective solutions for SoC design at mainstream and advanced, including 7nm, 6nm, 5nm and 4nm processes. Alchip has built its reputation as a high-performance ASIC leader through its advanced 2.5D/3D package services, CoWoS/chiplet design and manufacturing experience. Customers include global leaders in AI, HPC/supercomputer, mobile phones, entertainment device, networking equipment and other electronic product categories. Alchip is listed on the Taiwan Stock Exchange (TWSE: 3661), is a TSMC-certified Value Chain Aggregator and is a founding member of the new TSMC 3DFabric Alliance®.

Attachment

Charles Byers
Alchip Technologies
+ (408)-310-9244
chuck_byers@alchip.com

GlobeNewswire Distribution ID 8703971